Cronos Group Inc. Files 8-K with Material Agreement

TL;DR

CRON filed an 8-K on 12/9/25 for a material agreement - details TBD.

AI Summary

Cronos Group Inc. filed an 8-K on December 9, 2025, reporting an entry into a material definitive agreement, a Regulation FD disclosure, and financial statements/exhibits. The filing does not specify the nature of the agreement or provide financial details.

Why It Matters

This filing indicates a significant event for Cronos Group Inc., potentially impacting its business operations or financial standing, though details are not yet disclosed.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, which could represent a significant event, but the lack of specific details makes it difficult to assess the immediate risk.

Key Players & Entities

• Cronos Group Inc. (company) — Registrant
• December 9, 2025 (date) — Date of earliest event reported
• 001-38403 (other) — SEC File Number
• 4491 Concession Rd 12 Stayner , Ontario L0M 1S0 (address) — Principal executive offices

FAQ

Filing Documents

• cron-20251209.htm (8-K) — 40KB
• exhibit21-sharepurchaseagr.htm (EX-2.1) — 880KB
• exhibit991-pressreleasexca.htm (EX-99.1) — 39KB
• image_0.jpg (GRAPHIC) — 3KB
• image_0b.jpg (GRAPHIC) — 10KB
• 0001656472-25-000118.txt ( ) — 1224KB
• cron-20251209.xsd (EX-101.SCH) — 2KB
• cron-20251209_def.xml (EX-101.DEF) — 10KB
• cron-20251209_lab.xml (EX-101.LAB) — 22KB
• cron-20251209_pre.xml (EX-101.PRE) — 18KB
• cron-20251209_htm.xml (XML) — 3KB

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. On December 9, 2025 , Cronos Group Inc. (the "Company"), and its wholly owned subsidiary, CGM B.V. ("Dutch BidCo"), entered into a Share Sale and Purchase Agreement (the "Purchase Agreement") with "Ring" International Holding AG ("Ring") and Landewyck Tobacco S.A. ("Landewyck," and together with Ring, the "Sellers") for the acquisition of CanAdelaar B.V., a private company with limited liability ("CanAdelaar"), one of ten licensed cannabis growers in the Dutch Controlled Cannabis Supply Chain Experiment (the "Experiment"). Upon the terms and subject to the conditions set forth in the Purchase Agreement, the Company, through Dutch BidCo, will acquire all of the issued and outstanding share capital of CanAdelaar, resulting in CanAdelaar becoming a wholly owned subsidiary of the Company (the "Transaction"). The Transaction, which was unanimously approved by the Company's Board of Directors, is expected to close in the first half of 2026. Pursuant to the Purchase Agreement, the Company will pay (i) approximately 57.5 million in cash on a debt-free, cash free basis at closing (subject to certain customary adjustments), (ii) an amount of cash equal to fifty percent of CanAdelaar's 2026 Normalised EBITDA (as defined in the Purchase Agreement), which amount is expected to be paid in 2027 and (iii) an amount of cash equal to fifty percent of CanAdelaar's 2027 Normalised EBITDA, which amount is expected to be paid in 2028. The consummation of the Transaction is subject to certain customary conditions to closing, including (i) written unconditional confirmation in form and substance satisfactory to Dutch BidCo from the Dutch Minister of Health, Welfare and Sport (the "Minister") that the Transaction does not constitute grounds for revocation of CanAdelaar's license under the Experiment and that the Minister will not revoke or seek to remove CanAdelaar's license in the context of the Transaction, (ii) written confirmatio

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On December 9, 2025, the Company issued a press release announcing the entry into the Purchase Agreement, a copy of which is attached as Exhibit 99.1 and is incorporated herein by reference. The information furnished pursuant to Item 7.01 on this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing. Information about Forward-looking Statements This communication may contain information that may constitute "forward-looking information" or "forward-looking statements" within the meaning of applicable Canadian and U.S. securities laws and court decisions (collectively, "Forward-looking Statements"). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. Some of the Forward-looking Statements contained in this communication include statements about the expected closing of the Transaction, the receipt of regulatory approvals required to close the Transaction, the payment of the purchase price and the operations of CanAdelaar prior to the closing of the Transaction. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks. Financial results, p

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 2.1 * Share Sale and Purchase Agreement, dated as of December 9, 2025, by and among Cronos Group Inc., CGM B.V., "Ring" International Holding AG and Landewyck Tobacco S.A. 99.1 Press release issued by Cronos Group Inc., dated December 9, 2025. 104 Cover Page Interactive Data File – The cover page from Cronos Group Inc.'s Current Report on Form 8-K filed on December 9, 2025 is formatted in Inline XBRL. * Schedules and Exhibits are omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedules and exhibits to the Securities and Exchange Commission upon request; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedule or exhibit so furnished.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CRONOS GROUP INC. Dated: December 9, 2025 By: /s/ Michael Gorenstein Name: Michael Gorenstein Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR